APA

Eichenauer D. A., Plütschow A., Kreissl S., Sökler M., Hellmuth J. C., Meissner J., Mathas S., Topp M. S., Behringer K., Klapper W., Kuhnert G., Dietlein M., Kobe C., Fuchs M., Diehl V., Engert A. & Borchmann P. (20171215). Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. : The Lancet. Oncology.

Chicago

Eichenauer Dennis A, Plütschow Annette, Kreissl Stefanie, Sökler Martin, Hellmuth Johannes C, Meissner Julia, Mathas Stephan, Topp Max S, Behringer Karolin, Klapper Wolfram, Kuhnert Georg, Dietlein Markus, Kobe Carsten, Fuchs Michael, Diehl Volker, Engert Andreas and Borchmann Peter. 20171215. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. : The Lancet. Oncology.

Harvard

Eichenauer D. A., Plütschow A., Kreissl S., Sökler M., Hellmuth J. C., Meissner J., Mathas S., Topp M. S., Behringer K., Klapper W., Kuhnert G., Dietlein M., Kobe C., Fuchs M., Diehl V., Engert A. and Borchmann P. (20171215). Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. : The Lancet. Oncology.

MLA

Eichenauer Dennis A, Plütschow Annette, Kreissl Stefanie, Sökler Martin, Hellmuth Johannes C, Meissner Julia, Mathas Stephan, Topp Max S, Behringer Karolin, Klapper Wolfram, Kuhnert Georg, Dietlein Markus, Kobe Carsten, Fuchs Michael, Diehl Volker, Engert Andreas and Borchmann Peter. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. : The Lancet. Oncology. 20171215.